quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:21:58·59d
SECFiling
GeneDx Holdings Corp. logo

SEC Form 10-K filed by GeneDx Holdings Corp.

WGS· GeneDx Holdings Corp.
Technology
Full content unavailable. See the original source below.
Original source

Companies

  • WGS
    GeneDx Holdings Corp.
    Technology

Recent analyst ratings

  • Feb 9UpdateWells Fargo$155.00
  • Oct 20UpdateCanaccord Genuity$155.00
  • Jul 9UpdatePiper Sandler$110.00
  • May 15UpdateGuggenheim$88.00
  • May 9UpdateJefferies$80.00
  • Aug 28UpdateWells Fargo$34.00

Related

  • PR10d
    GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026
  • INSIDER24d
    SEC Form 4 filed by Feeley Kevin
  • INSIDER24d
    SEC Form 4 filed by Stueland Katherine
  • INSIDER37d
    CHIEF EXECUTIVE OFFICER Stueland Katherine sold $1,319,291 worth of shares (17,179 units at $76.80) and converted options into 30,671 shares, increasing direct ownership by 30% to 58,447 units (SEC Form 4)
  • INSIDER37d
    CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 11,012 shares and sold $438,203 worth of shares (5,706 units at $76.80), increasing direct ownership by 24% to 27,148 units (SEC Form 4)
  • PR43d
    Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
  • INSIDER43d
    SEC Form 4 filed by GeneDx Holdings Corp.
  • INSIDER43d
    SEC Form 4 filed by GeneDx Holdings Corp.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022